Foghorn Therapeutics (FHTX) Competitors $5.23 -0.15 (-2.79%) Closing price 04:00 PM EasternExtended Trading$5.36 +0.14 (+2.58%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends FHTX vs. SYRE, ETNB, OCUL, RCUS, AUPH, SPRY, ADPT, GYRE, MRVI, and PAHCShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Spyre Therapeutics (SYRE), 89bio (ETNB), Ocular Therapeutix (OCUL), Arcus Biosciences (RCUS), Aurinia Pharmaceuticals (AUPH), ARS Pharmaceuticals (SPRY), Adaptive Biotechnologies (ADPT), Gyre Therapeutics (GYRE), Maravai LifeSciences (MRVI), and Phibro Animal Health (PAHC). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. Spyre Therapeutics 89bio Ocular Therapeutix Arcus Biosciences Aurinia Pharmaceuticals ARS Pharmaceuticals Adaptive Biotechnologies Gyre Therapeutics Maravai LifeSciences Phibro Animal Health Foghorn Therapeutics (NASDAQ:FHTX) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, community ranking, risk, earnings and media sentiment. Does the MarketBeat Community favor FHTX or SYRE? Foghorn Therapeutics received 22 more outperform votes than Spyre Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Spyre Therapeutics an outperform vote while only 63.49% of users gave Foghorn Therapeutics an outperform vote. CompanyUnderperformOutperformFoghorn TherapeuticsOutperform Votes4063.49% Underperform Votes2336.51% Spyre TherapeuticsOutperform Votes18100.00% Underperform VotesNo Votes Do insiders and institutionals have more ownership in FHTX or SYRE? 61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 9.1% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 6.2% of Spyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is FHTX or SYRE more profitable? Spyre Therapeutics has a net margin of 0.00% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-357.53% N/A -30.98% Spyre Therapeutics N/A -210.01%-44.40% Which has more volatility and risk, FHTX or SYRE? Foghorn Therapeutics has a beta of 3.18, meaning that its share price is 218% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.85, meaning that its share price is 185% more volatile than the S&P 500. Do analysts recommend FHTX or SYRE? Foghorn Therapeutics presently has a consensus target price of $13.17, suggesting a potential upside of 144.73%. Spyre Therapeutics has a consensus target price of $54.83, suggesting a potential upside of 144.68%. Given Foghorn Therapeutics' higher probable upside, research analysts clearly believe Foghorn Therapeutics is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media prefer FHTX or SYRE? In the previous week, Spyre Therapeutics had 5 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 6 mentions for Spyre Therapeutics and 1 mentions for Foghorn Therapeutics. Foghorn Therapeutics' average media sentiment score of 1.94 beat Spyre Therapeutics' score of 0.61 indicating that Foghorn Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Spyre Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation and earnings, FHTX or SYRE? Foghorn Therapeutics has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$34.15M8.76-$98.43M-$1.92-2.80Spyre Therapeutics$890K1,295.02-$338.79M-$7.47-3.00 SummaryFoghorn Therapeutics beats Spyre Therapeutics on 11 of the 18 factors compared between the two stocks. Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$299.18M$6.99B$5.80B$9.11BDividend YieldN/A2.88%5.28%3.98%P/E Ratio-2.806.1625.9119.13Price / Sales8.76315.42474.53119.58Price / CashN/A75.0445.1138.24Price / Book-2.946.547.655.12Net Income-$98.43M$138.11M$3.18B$245.96M7 Day Performance-12.23%-0.74%-0.49%-0.89%1 Month Performance22.00%-0.16%1.84%-0.51%1 Year Performance-9.88%-1.82%18.66%16.50% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.7172 of 5 stars$5.23-2.8%$13.17+151.8%-9.0%$290.85M$25.52M-2.72120Positive NewsSYRESpyre Therapeutics2.1054 of 5 stars$22.75+0.4%$54.83+141.0%+2.1%$1.17B$890,000.00-3.05100Analyst UpgradeNews CoverageETNB89bio3.1726 of 5 stars$10.98-3.8%$31.43+186.2%+10.8%$1.17BN/A-3.7740Analyst ForecastOCULOcular Therapeutix3.3896 of 5 stars$7.39-2.4%$17.00+130.0%-3.6%$1.16B$61.44M-5.60230RCUSArcus Biosciences2.7933 of 5 stars$12.50-0.4%$32.67+161.2%-35.2%$1.14B$117M-3.97500Analyst ForecastAnalyst RevisionNews CoverageGap UpAUPHAurinia Pharmaceuticals2.6032 of 5 stars$7.97-0.5%$10.00+25.5%+40.1%$1.14B$220.36M-53.13300Analyst DowngradeNews CoverageSPRYARS Pharmaceuticals2.8846 of 5 stars$11.74-1.5%$28.80+145.3%+56.6%$1.14B$30,000.00-23.0290News CoverageGap UpADPTAdaptive Biotechnologies3.6903 of 5 stars$7.68-2.0%$7.38-4.0%+116.4%$1.13B$170.28M-5.73790Analyst ForecastInsider TradeGYREGyre Therapeutics0.2509 of 5 stars$11.91-1.6%N/A-17.0%$1.11B$105.03M0.0040MRVIMaravai LifeSciences4.0282 of 5 stars$4.30-6.1%$10.28+139.1%-25.8%$1.09B$288.95M-2.62610Options VolumeNews CoverageGap UpPAHCPhibro Animal Health3.9307 of 5 stars$26.22+10.7%$21.00-19.9%+88.0%$1.06B$1.11B54.631,940Analyst RevisionHigh Trading Volume Related Companies and Tools Related Companies Spyre Therapeutics Competitors 89bio Competitors Ocular Therapeutix Competitors Arcus Biosciences Competitors Aurinia Pharmaceuticals Competitors ARS Pharmaceuticals Competitors Adaptive Biotechnologies Competitors Gyre Therapeutics Competitors Maravai LifeSciences Competitors Phibro Animal Health Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FHTX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
